Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02413918 · ClinicalTrials.gov registry record · Phase 4

Iloperidone in Mixed States of Bipolar Disorder

A Phase 4 study of Bipolar Disorder, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 4
Development phase
41
Enrollment target
1
Study location

NCT02413918 is a Phase 4 study of Bipolar Disorder that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 41 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02413918, a Phase 4 study of Bipolar Disorder, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 4
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD. 2. To assess background, baseline features, and behavioral components which characterize treatment response/non-response in the acute and long term management of MS

Conditions Studied

Interventions

  • DRUG iloperidone

Study Locations (1)

Texas

  • UT Health Science Center San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2012-04
Est. Completion 2015-04
Phase Phase 4

What the Registry Record Tells You About NCT02413918

The ClinicalTrials.gov registry entry for NCT02413918 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (88% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which iloperidone is the first listed.

NCT02413918 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02413918 about?

NCT02413918 is a clinical study titled "Iloperidone in Mixed States of Bipolar Disorder". 1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD. 2. To assess backgrou...

What is the current status of trial NCT02413918?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2012-04. Estimated completion is 2015-04.

What conditions does trial NCT02413918 study?

This clinical trial studies the following conditions: Bipolar Disorder.

What interventions are being tested in trial NCT02413918?

The interventions under investigation include: iloperidone (DRUG).

Who is sponsoring clinical trial NCT02413918?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02413918 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.